DE69733649D1 - Calcylitische verbindungen - Google Patents

Calcylitische verbindungen

Info

Publication number
DE69733649D1
DE69733649D1 DE69733649T DE69733649T DE69733649D1 DE 69733649 D1 DE69733649 D1 DE 69733649D1 DE 69733649 T DE69733649 T DE 69733649T DE 69733649 T DE69733649 T DE 69733649T DE 69733649 D1 DE69733649 D1 DE 69733649D1
Authority
DE
Germany
Prior art keywords
calcylitic
compounds
calcylitic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69733649T
Other languages
English (en)
Other versions
DE69733649T2 (de
Inventor
Wagenen C Van
Mar G Del
Derek Sheehan
M Barmore
M Keenan
R Kotecha
Mervyn Thompson
F Callahan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Shire NPS Pharmaceuticals Inc
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp, NPS Pharmaceuticals Inc filed Critical SmithKline Beecham Ltd
Publication of DE69733649D1 publication Critical patent/DE69733649D1/de
Application granted granted Critical
Publication of DE69733649T2 publication Critical patent/DE69733649T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes
DE69733649T 1996-04-09 1997-04-04 Calcylitische verbindungen Expired - Lifetime DE69733649T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32263 1987-03-31
US62960896A 1996-04-09 1996-04-09
US629608 1996-04-09
US3226396P 1996-12-03 1996-12-03
PCT/US1997/005558 WO1997037967A1 (en) 1996-04-09 1997-04-04 Calcilytic compounds

Publications (2)

Publication Number Publication Date
DE69733649D1 true DE69733649D1 (de) 2005-08-04
DE69733649T2 DE69733649T2 (de) 2006-05-18

Family

ID=26708193

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733649T Expired - Lifetime DE69733649T2 (de) 1996-04-09 1997-04-04 Calcylitische verbindungen

Country Status (19)

Country Link
US (2) US6022894A (de)
EP (1) EP0901459B1 (de)
JP (1) JP2001501584A (de)
CN (1) CN1254465C (de)
AR (1) AR008586A1 (de)
AT (1) ATE298739T1 (de)
AU (1) AU726659B2 (de)
BR (1) BR9708632A (de)
CA (1) CA2251331C (de)
CO (1) CO4820431A1 (de)
DE (1) DE69733649T2 (de)
EA (1) EA002984B1 (de)
HK (1) HK1018899A1 (de)
IL (1) IL126458A (de)
NZ (1) NZ332068A (de)
PL (1) PL191027B1 (de)
SA (1) SA97180135B1 (de)
SG (1) SG99290A1 (de)
WO (1) WO1997037967A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
AU2351699A (en) * 1998-01-30 1999-08-16 Brigham And Women's Hospital The human calcium-sensing receptor in the detection and treatment of cancer
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
PE20000415A1 (es) * 1998-04-08 2000-05-21 Smithkline Beecham Corp Compuestos calciliticos
CA2245903A1 (en) 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
ECSP003590A (es) * 1999-07-31 2002-02-25 Smithkline Beecham Corp Compuestos calcioliticos
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
AR030684A1 (es) * 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
IL154058A0 (en) * 2000-07-21 2003-07-31 Smithkline Beecham Corp Calcilytic compounds
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
EP1308436B1 (de) 2000-08-11 2008-10-15 Japan Tobacco Inc. Calciumrezeptor-antagonisten
EP1383511B1 (de) * 2000-10-25 2006-10-25 SmithKline Beecham Corporation Kalzilytische verbindungen
CA2481508A1 (en) 2002-04-12 2003-10-23 Schering Corporation G-protein coupled receptor ligands and methods
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
FR2847250B1 (fr) * 2002-11-15 2006-09-22 Oreal Composition, notamment cosmetique, comprenant une amine secondaire ou tertiaire
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
WO2004069793A2 (en) * 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
ES2337576T3 (es) 2003-04-23 2010-04-27 Japan Tobacco Inc. Antagonista decasr.
EP1630157A4 (de) 2003-05-28 2007-05-23 Japan Tobacco Inc Casr-antagonist
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
WO2005065050A2 (ja) 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation ２環化合物
US20080234370A1 (en) * 2004-02-06 2008-09-25 Marquis Robert W Calcilytic Compounds
US7531518B2 (en) 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
EP1757582B1 (de) 2004-05-28 2015-12-30 Mitsubishi Tanabe Pharma Corporation Arylalkylamine und verfahren zu deren herstellung
US20080069814A1 (en) * 2005-01-05 2008-03-20 Novacea, Inc. Prevention of Thrombotic Disorders with Active Vitamin D Compounds or Mimics Thereof
EP1871386A1 (de) * 2005-04-22 2008-01-02 Novacea, Inc. Behandlung, vorbeugung und besserung von lungenerkrankungen in verbindung mit chemotherapie oder radiotherapie mit aktiven vitamin-d-verbindungen oder mimetika davon
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
EP1937233B1 (de) 2005-09-02 2013-01-09 Amgen Inc. Modulierung des darmflüssigkeitsgleichgewichtes mittels calcimimetika
ES2335360T3 (es) * 2005-11-25 2010-03-25 Galapagos Sas Derivados de urea utiles como moduladores de los receptores de calcio.
WO2009055631A1 (en) * 2007-10-25 2009-04-30 Smithkline Beecham Corporation Calcilytic compounds
PT2292592E (pt) * 2008-06-05 2012-11-12 Asahi Kasei Pharma Corp Composto de sulfonamida e sua aplicação
EP2196461A1 (de) 2008-12-15 2010-06-16 Bayer CropScience AG 4-Amino-1,2,3-benzoxathiazin-Derivate als Pestizide
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN103601645B (zh) * 2013-11-07 2016-05-25 上海适济生物科技有限公司 1-(苯乙基氨基)丙烷-2-醇类化合物或其盐的制备方法
WO2019153216A1 (zh) * 2018-02-09 2019-08-15 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
EP4069669A1 (de) * 2019-12-05 2022-10-12 Syngenta Crop Protection AG Verfahren in einem schritt zur herstellung von phenylethylamin-derivaten
CN116199605A (zh) * 2023-02-27 2023-06-02 上海睿腾医药科技有限公司 一种5-氯-2-羟基-二甲基苯磺酰胺的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (de) *
GB1129072A (en) * 1966-02-01 1968-10-02 Ici Ltd Benzofuran and indole derivatives
GB1058822A (en) * 1963-07-30 1967-02-15 Ici Ltd 3-amino-2-hydroxypropoxy heterocyclic derivatives
GB1199037A (en) * 1967-09-27 1970-07-15 Ici Ltd Alkanolamine Derivatives
ES410417A1 (es) * 1973-01-08 1976-01-01 Andreu Sa Dr Procedimiento para la obtencion de aminoalcoholes derivadosdel p-acetamidofenol.
SE388849B (sv) * 1974-02-14 1976-10-18 Haessle Ab Forfarande for framstellning av nya aminer med beta-receptorstimulerande verkan
DE2530613A1 (de) * 1974-11-01 1976-05-06 Haessle Ab Aminderivate, verfahren zu deren herstellung und sie enthaltende arzneimittel
US4067904A (en) * 1975-12-19 1978-01-10 Mead Johnson & Company Alkylsulfonylphenoxypropanolamine derivatives
JPS5936617B2 (ja) * 1976-03-05 1984-09-05 大塚製薬株式会社 カルボスチリル誘導体
CH619453A5 (de) * 1976-03-17 1980-09-30 Otsuka Pharma Co Ltd
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
DE2830211A1 (de) * 1977-07-21 1979-02-01 Sandoz Ag Substituierte indol-derivate, ihre herstellung und verwendung
EP0002792A1 (de) * 1978-01-03 1979-07-11 Sandoz Ag 3-Aminopropoxyaryl-Derivate, ihre Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DK267779A (da) * 1978-06-27 1979-12-28 Merck & Co Inc Fr&mgangsmaade til fremstilling af n-aralkylamino-propoxycyanopyridiner
CH636856A5 (en) * 1978-07-17 1983-06-30 Sandoz Ag 4-(3-Aminopropoxy)indole derivatives, their preparation and medicines containing them
DE2914166A1 (de) * 1979-04-07 1980-10-23 Beiersdorf Ag Arylsubstituierte furane und verfahren zu ihrer herstellung
ES480066A1 (es) * 1979-04-28 1980-04-01 Especialid Latin Medicam Unive Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos.
DE2943406A1 (de) * 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen Aminoderivate des 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazols
DE2944222A1 (de) * 1979-11-02 1981-05-14 Basf Ag, 6700 Ludwigshafen Neue aminoderivate des 1,2-benzisothiazols
JPS568319A (en) * 1980-03-26 1981-01-28 Otsuka Pharmaceut Co Ltd Antihistamine
US4332787A (en) * 1980-06-23 1982-06-01 The Massachusetts General Hospital Assay for beta-adrenergic antagonists and antibody therefor
JPS5780321A (en) * 1980-11-05 1982-05-19 Otsuka Pharmaceut Co Ltd Cardiotonic agent
US4376125A (en) * 1980-11-05 1983-03-08 University Of Virginia Alumni Patents Foundation Aminobenzlpropranolol and pharmaceutical preparation thereof
EP0095454A3 (de) * 1982-05-13 1985-04-03 Gerot-Pharmazeutika Gesellschaft m.b.H. Neue kernsubstituierte Pyrogallol-Derivate
DE3301198A1 (de) * 1983-01-15 1984-07-19 Hoechst Ag, 6230 Frankfurt N-arylalkylamin-3-propoxypyridin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
US4517188A (en) * 1983-05-09 1985-05-14 Mead Johnson & Company 1-Pyrimidinyloxy-3-hetaryl-alkylamino-2-propanols
DK17386A (da) * 1985-01-15 1986-07-16 Glaxo Group Ltd Aminderivater
GB2192394A (en) * 1986-07-11 1988-01-13 Glaxo Group Ltd Amine derivatives
US5053514A (en) * 1988-08-10 1991-10-01 Otsuka Pharmaceutical Company, Limited Cardiotonics
DE4040186A1 (de) * 1989-12-20 1991-06-27 Hoechst Ag Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten
DE4017019A1 (de) * 1990-05-26 1991-11-28 Hoechst Ag Verwendung von substituierten ss-hydroxyethylaminen als potente hemmstoffe der exoenzyme von pilzen
ES2108120T3 (es) * 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
DK0724561T3 (da) * 1991-08-23 2004-06-28 Nps Pharma Inc Calciumreceptoraktive arylalkylaminer
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
EP1281702B1 (de) * 1991-08-23 2005-12-21 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
KR100296899B1 (ko) * 1993-02-23 2001-10-24 쉘비 칼베르그 모르스 칼슘수용체활성분자
GB9312893D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.

Also Published As

Publication number Publication date
NZ332068A (en) 2001-03-30
IL126458A0 (en) 1999-08-17
CO4820431A1 (es) 1999-07-28
DE69733649T2 (de) 2006-05-18
CA2251331C (en) 2009-06-09
CN1221401A (zh) 1999-06-30
EA002984B1 (ru) 2002-12-26
AU2607097A (en) 1997-10-29
US6521667B1 (en) 2003-02-18
PL329314A1 (en) 1999-03-15
BR9708632A (pt) 2000-01-18
IL126458A (en) 2004-06-20
SA97180135B1 (ar) 2006-06-12
AR008586A1 (es) 2000-02-09
AU726659B2 (en) 2000-11-16
JP2001501584A (ja) 2001-02-06
WO1997037967A1 (en) 1997-10-16
EP0901459B1 (de) 2005-06-29
HK1018899A1 (en) 2000-01-07
EA199800913A1 (ru) 1999-06-24
US6022894A (en) 2000-02-08
EP0901459A1 (de) 1999-03-17
PL191027B1 (pl) 2006-03-31
CA2251331A1 (en) 1997-10-16
CN1254465C (zh) 2006-05-03
ATE298739T1 (de) 2005-07-15
SG99290A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
ATE298739T1 (de) Calcylitische verbindungen
ATE208377T1 (de) Substituierte benzylaminopiperloin verbindungen
ATE206701T1 (de) Östrogene verbindungen
ID19403A (id) Senyawa-senyawa heterosiklik
ID19609A (id) Senyawa-senyawa heterosiklik
ID16152A (id) Senyawa-senyawa triaril
ID15904A (id) Senyawa-senyawa tiofenopirimidina
ID19430A (id) Senyawa senyawa heterosiklik
BR9709230A (pt) Composto
ATE218536T1 (de) Entzündungshemmende verbindungen
ID19476A (id) Senyawa piridilpirol
BR9707051A (pt) Composto
DE69807397T2 (de) Triazinylaminostilben Verbindungen
DE69716924D1 (de) Phosphonat-nukleotid-verbindungen
ID18685A (id) Senyawa trisiklik tersubstitusi
DE69808403D1 (de) Tetradecachlorcyclohexasilandianon enthaltende Verbindungen
BR9705635A (pt) Compostos
ATE258921T1 (de) Aryl-annellierte azapolycyclische verbindungen
ATE405580T1 (de) Antithrombotische verbindungen
DE69531522D1 (de) Heterozyklische Verbindungen
ATE225364T1 (de) Bromotiacumicin verbindungen
BR9711205A (pt) Composto
DE69709659T2 (de) Halopropargyl-einschlussverbindungen
DE59803962D1 (de) Polycyclische Verbindungen
EE9900012A (et) Uudsed ühendid

Legal Events

Date Code Title Description
8364 No opposition during term of opposition